NEW YORK — The S&P 500 plummeted 4 percent on Thursday, Nov. 5, erasing roughly $3 trillion in market value in its worst day since the April 2025 tariff crash. The Nasdaq Composite entered correction territory while the PHLX Semiconductor Index collapsed 12 percent, its sharpest decline since March 2020.
The carnage was concentrated in artificial intelligence and data-center stocks. Chipmakers bore the brunt. The VIX, Wall Street's fear gauge, surged 70 percent to 25.64—a move this severe has occurred only eight times since 1991.
Friday offered only muted relief: the S&P 500 closed up 0.31 percent at 7,376.86, leaving the week on track for its worst performance since June.
Historically, the S&P 500 has averaged a 3 percent gain one month after VIX spikes of this magnitude and 7.1 percent three months later. But near-term drawdowns punish momentum portfolios.
That's where beta matters. Jazz Pharmaceuticals (NASDAQ: JAZZ) trades at 0.35 beta—roughly one-third the volatility of the broad market. With a $15.07 billion market cap, the company has risen 8.7 percent over the past five days while the index cratered.
The fundamentals justify the defensive label. JAZZ posted record third-quarter revenue of $1.2 billion, up 10 percent year-over-year, spread across multiple drug franchises. Forward P/E of 8.82 suggests room for multiple expansion if the market reprices low-beta healthcare as a rotation plays out.
Institutional conviction is real: 46 hedge funds held positions in JAZZ as of Q2 2026. In a market where momentum names face margin calls and forced selling, a 0.35-beta compounder compounds.
